Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $2.60M by Medicaid between Jan 2018 and Jul 2019, across 42 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
KINGS MOUNTAIN, NC 28086
KINGS MOUNTAIN, NC 28086
33aNPI1558765529assigned 10/20/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.60M
24GClaims38,945
24DCodes billed42
24AFirst – last monthJan 2018 – Jul 2019
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#71 of 92
Median peer was paid$11.47M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,339 | $1.53M | |
| 2019 | 13,606 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 9,129 | 8,464 | $1.10M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 5,578 | 5,119 | $777K |
| 41899 | Unlisted procedure, dentoalveolar structures | 18% | 356 | 334 | $459K |
| J3490 | Unclassified drugs | 2.7% | 9,494 | 6,158 | $71K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 1,152 | 1,067 | $45K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.7% | 349 | 319 | $44K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 2,726 | 2,531 | $37K |
| 80047 | <1% | 1,553 | 1,397 | $16K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 886 | 817 | $10K |
| 81001 | <1% | 3,010 | 2,793 | $9K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 47 | 46 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 175 | 168 | $5K |
30 more codes
| 27096 | <1% | 50 | $3K | |
| 81025 | <1% | 482 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 462 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 188 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 92 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 58 | $2K |
| 62323 | <1% | 14 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 377 | $1K |
| 85027 | <1% | 272 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 231 | $999.27 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 72 | $994.40 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 349 | $686.51 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 419 | $577.72 |
| J2704 | Injection, propofol, 10 mg | <1% | 350 | $538.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 338 | $532.56 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 182 | $339.01 |
| 71045 | Radiologic examination, chest; single view | <1% | 30 | $302.53 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $271.50 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $252.14 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 215 | $236.37 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13 | $109.89 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 99 | $93.49 |
| 84484 | <1% | 14 | $73.56 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14 | $58.96 |
| 85014 | <1% | 15 | $56.15 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12 | $35.10 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14 | $27.75 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 75 | $24.23 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $9.05 |
| 82962 | <1% | 12 | $2.92 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EXECTUVIE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.